Biotech Strategy Blog

Commentary on Science, Innovation & New Products with a focus on Oncology, Hematology & Cancer Immunotherapy

Posts tagged ‘CEA-IL2’

ASCO 2014 Chicago Contemplation

Contemplation in Chicago ahead of #ASCO17

As part of our ongoing American Society of Clinical Research (#ASCO17) Preview series (we’re on number 5 already), we turn our attention to an upcoming area of cancer research that is expected to play an important role in future clinical trials and combination regimens because of the mechanism of action involved.

It may also turn out to be a very handy and important approach for turning cold into hot tumours.

To learn more, subscribers can login to read our latest insights and analysis or you can gain assess via the blue box below….

Photo: National Institutes of Health

After last week’s post on therapeutic tumor infiltrating lymphocytes (TILs), we received a bunch of questions from readers.

I don’t have time to answer them all in detail individually (sorry!), but it does provide an opportunity to review the evolving landscape and address some of them within the latest article.

It seems to be a good time to take a broader look at T cell manipulation, especially as it pertains to the application of TILs, chimeric antigen receptors (CAR), and T cell receptors (TCR).

We’ve certainly come along way since the historic lecture in 1991 pictured right (photo: National Institutes of Health), but there’s still some way to go before the full potential of cancer immunotherapy is reached.

Subscribers can login in below or you can sign up by clicking on the blue icon at the end of the post.

error: Content is protected !!